Sekretariat Ditjen Pencegahan DAN P Pharmaceutical Import Profile — Indonesia (DGFT 2022–2026)

Name: Sekretariat Ditjen Pencegahan DAN P Pharmaceutical Import Records from India — 5 Products, $5.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sekretariat Ditjen Pencegahan DAN P — Pharmaceutical Importer Profile (2026) | 5 Products, $5.3M Trade | TransData Nexus

Sekretariat Ditjen Pencegahan DAN P

Pharmaceutical Importer · Indonesia · Tuberculosis Medications Focus · $5.3M Total Trade · DGFT Verified

Sekretariat Ditjen Pencegahan DAN P is a pharmaceutical importer based in Indonesia with a total trade value of $5.3M across 5 products in 3 therapeutic categories. Based on 105 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Sekretariat Ditjen Pencegahan DAN P sources from 4 verified Indian suppliers, with Lupin Limited accounting for 38.0% of imports.

Sekretariat Ditjen Pencegahan DAN P — Import Portfolio & Supplier Network

Sekretariat Ditjen Pencegahan DAN P import network — 5 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Sekretariat Ditjen Pencegahan DAN P?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$773.5K	18	38.0%
Macleods Pharmaceuticals Limited	$682.0K	15	33.5%
Maneesh Pharmaceuticals Limited

What Formulations Does Sekretariat Ditjen Pencegahan DAN P Import?

Formulation	Value	Ships
Stop tb cat i & iii patient kit-a (gdf)rifampicin 150MG+ isoniazide 75MG+ pyrazinamide 400MG+ ethambutol 275MG)	$450.0K	9
Stop tb cat i & iii patient kit-a (gdf)rifampicin 150MG+ isoniazide 75MG+ pyrazinamide 400MG+ ethambutol 275MG)	$200.0K	4
Cycloserine capsules USP 250 MG	$150.0K	3
6 strips of 28 tablets Each of rifampicin 150 MG/isoniazid 75 MG/pyrazinamide 400MG/ethambutol hcl 275MG tablets(25602	$150.0K	3
12 strips of 28 tablets Each of rifampicin 150 MG/ isoniazid 75 MG tablets (25602 cartons	$150.0K	3
Rifampin and isoniazid dispersible tablets-rifa 75 & iso 50 TAB 3x28t gdf (pedia) (batch no-a310705 ,a310739,a310784)	$123.5K	3
Isoniazid 300MG/rifapentine 300MG tablets Pack size:3x12's6557 Pack batch no: nie2323a/nie2324a manufacturing .dt.: may-2023	$100.0K	2
Isoniazid 300MG and rifapentine 300MG	$50.0K	1
Isoniazid 300MG / rifapentine 300MG	$50.0K	1
Cycloserine capsules USP 250 MG. 10x10's 14490	$50.0K	1
Pretomanid 200MG tablets 26's dovprela 14231 packs : 26's	$50.0K	1
Isoniazid 300MG / rifapentine 300MG tablets. 3x12's 21401	$50.0K	1
Rifampicin 75 MG / isoniazid 50 MG dispersible tablets. 3x28's 28255	$50.0K	1
Isoniazid 300MG / rifapentine 300MG tablets. 3x12's 21400	$50.0K	1
Sofosbuvir 400MG + daclatasvir 60MG tablets 28's - myhep dvir 8978 packs : 28's	$50.0K	1

Sekretariat Ditjen Pencegahan DAN P imports 29 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 5 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isoniazid	Tuberculosis Medications	$1.6M	32	0.1%	17
2	Rifampicin	Advanced Antibiotics	$1.3M	25	0.1%	16
3	Ethambutol	Tuberculosis Medications	$900.0K	18	0.1%	10
4	Pyrazinamide	Tuberculosis Medications	$850.0K	17	0.1%	5
5	Kit	Medical Devices & Diagnostics	$650.0K	13	0.1%	13

Sekretariat Ditjen Pencegahan DAN P imports 5 pharmaceutical products across 3 categories into Indonesia totaling $5.3M.

Sekretariat Ditjen Pencegahan DAN P — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Sekretariat Ditjen Pencegahan dan Pengendalian Penyakit (Sekretariat Ditjen P2P) is the Secretariat of the Directorate General of Disease Prevention and Control within Indonesia's Ministry of Health. This governmental body is responsible for coordinating and supporting administrative functions related to disease prevention and control programs across the nation. Their role encompasses the development and management of plans, programs, activities, and budgets pertinent to public health initiatives. Additionally, they oversee financial reporting, asset management, quality assurance, risk management, and the formulation of regulations and agreements within the Directorate General. (p2.kemkes.go.id)

While Sekretariat Ditjen P2P does not function as a pharmaceutical wholesaler or distributor, it plays a pivotal role in the procurement and distribution of medical supplies and pharmaceuticals necessary for disease prevention and control efforts. Their activities are integral to ensuring the availability and accessibility of essential medicines and medical devices throughout Indonesia.

2Distribution Network

As a governmental entity, Sekretariat Ditjen P2P's distribution network is designed to ensure the efficient and equitable distribution of medical supplies and pharmaceuticals across Indonesia. While specific details about their warehouse locations and logistics capabilities are not publicly disclosed, their operations are structured to cover the entire archipelago, facilitating timely delivery to both urban and remote areas. This extensive reach is crucial for maintaining public health standards and effectively managing disease prevention and control programs nationwide.

3Industry Role

In Indonesia's pharmaceutical supply chain, Sekretariat Ditjen P2P serves as a central procurement and distribution entity. Although it does not operate as a traditional wholesaler or distributor, its role is critical in sourcing and supplying medical products required for public health initiatives. By coordinating with various suppliers and managing the logistics of medical supplies, Sekretariat Ditjen P2P ensures that essential pharmaceuticals and medical devices are available to healthcare facilities and programs across the country.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Sekretariat Ditjen Pencegahan DAN P

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Sekretariat Ditjen P2P's sourcing strategy exhibits a high degree of concentration, with a total import value of $5.3 million USD from India over 105 shipments, encompassing five products across three therapeutic categories. The top five imported products—isoniazid, rifampicin, ethambutol, pyrazinamide, and kits—account for 100% of their imports from India. This singular focus on a limited product range suggests a strategic emphasis on specific therapeutic areas, likely driven by prevailing public health needs and disease control priorities.

The reliance on a narrow product portfolio may present risks related to supply chain disruptions or changes in public health priorities. However, this concentration also indicates a targeted approach to addressing specific health challenges, such as tuberculosis, through the procurement of essential medications. The stability of their supplier relationships, particularly with key Indian manufacturers like Lupin Limited and Macleods Pharmaceuticals Limited, is crucial for maintaining a consistent supply of these critical products.

2Supply Chain Resilience

Sekretariat Ditjen P2P's supply chain resilience is closely tied to its partnerships with Indian pharmaceutical manufacturers. The organization's import data reveals engagements with four unique suppliers, with Lupin Limited and Macleods Pharmaceuticals Limited being the primary contributors. This limited supplier base may expose the supply chain to risks associated with geopolitical tensions, regulatory changes, or production issues in India.

Importing Pharmaceuticals into Indonesia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Indonesia

1Regulatory Authority & Framework

Indonesia's pharmaceutical import regulations are primarily governed by the Ministry of Trade (MoT) and the National Agency of Drug and Food Control (Badan POM). The MoT oversees the importation of goods, including pharmaceuticals, and issues regulations such as Minister of Trade Regulation No. 8 of 2024, which outlines technical rules for importing products across various industry sectors.

Badan POM is responsible for the pre-market and post-market oversight of drugs and foods in Indonesia. This includes ensuring that imported pharmaceuticals meet safety, efficacy, and quality standards. The Directorate of Drug Registration within Badan POM plays a crucial role in assessing and approving pharmaceutical products for the Indonesian market. (registrasiobat.pom.go.id)

2Import Licensing & GMP

Importers of pharmaceuticals in Indonesia must obtain an import business license (API) from the Ministry of Trade. There are two types of API licenses: API-U (General Importer) for trade and resale, and API-P (Producer Importer) for production inputs only.

Additionally, imported pharmaceutical products must comply with Good Manufacturing Practice (GMP) standards. Badan POM recognizes GMP certificates from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certificates from recognized authorities to guarantee product quality and safety. (farmalkes.kemkes.go.id)

Sekretariat Ditjen Pencegahan DAN P — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Sekretariat Ditjen P2P's product strategy focuses on importing essential medications for tuberculosis treatment, including isoniazid, rifampicin, ethambutol, pyrazinamide, and related kits. This targeted approach aligns with Indonesia's public health priorities, addressing the high prevalence of tuberculosis in the country. The demand for these products is driven by the need to provide effective treatment regimens to patients, thereby reducing transmission rates and improving health outcomes.

The emphasis on these specific therapeutic areas reflects a strategic decision to concentrate resources on combating diseases with significant public health impact. By focusing on a limited range of products, Sekretariat Ditjen P2P can streamline procurement processes and ensure the availability of high-quality medications essential for disease control efforts.

2Sourcing Profile

Sekretariat Ditjen P2P's sourcing strategy is centered on importing generic formulations from India, a major global supplier of affordable and high-quality generic pharmaceuticals. The organization's preference for finished pharmaceutical formulations, such as tablets, capsules, syrups, and injections, indicates a focus on ready-to-use products that meet the therapeutic needs of patients.

India's established pharmaceutical industry, characterized by its adherence to international quality standards and competitive pricing, makes it a strategic partner for Sekretariat Ditjen P2P. By sourcing from India, Sekretariat Ditjen P2P can ensure a consistent supply of essential medications while managing costs effectively.

Frequently Asked Questions — Sekretariat Ditjen Pencegahan DAN P

What products does Sekretariat Ditjen Pencegahan DAN P import from India?

Sekretariat Ditjen Pencegahan DAN P imports 5 pharmaceutical products across 3 categories. Top imports: Isoniazid ($1.6M), Rifampicin ($1.3M), Ethambutol ($900.0K), Pyrazinamide ($850.0K), Kit ($650.0K).

Who supplies pharmaceuticals to Sekretariat Ditjen Pencegahan DAN P from India?

Sekretariat Ditjen Pencegahan DAN P sources from 4 verified Indian suppliers. The primary supplier is Lupin Limited (38.0% of imports, $773.5K).

What is Sekretariat Ditjen Pencegahan DAN P's total pharmaceutical import value?

Sekretariat Ditjen Pencegahan DAN P's total pharmaceutical import value from India is $5.3M, based on 105 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Sekretariat Ditjen Pencegahan DAN P focus on?

Sekretariat Ditjen Pencegahan DAN P imports across 3 categories. The largest: Tuberculosis Medications (63.8%), Advanced Antibiotics (23.8%), Medical Devices & Diagnostics (12.4%).

Get Full Sekretariat Ditjen Pencegahan DAN P Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.